Open AccessDeferasirox in a refractory anemia after other treatment options: case report and literature review
Author(s) -
Manduzio Palma
Publication year - 2015
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.262
Subject(s) - deferasirox , medicine , intensive care medicine , refractory (planetary science) , physics , thalassemia , astrobiology
Key Clinical Message Deferasirox, represents an effective iron chelator drug in lower risk myelodysplastic syndromes. Reduction in oxidative stress is responsible of the hematologic improvement but further explanation may impact on its benefit. Biological and clinical studies are necessary to better define mechanisms of action, assess toxicities, and predicting factors of response.